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Abstract
Objective: Prandial insulin dosing is an empirical practice associated frequently with poor reproducibility in postprandial
glucose response. Based on continuous glucose monitoring (CGM), a method for prandial insulin administration (iBolus) is
presented and evaluated for people with type 1 diabetes using CSII therapy.
Subjects and Methods: An individual patient’s model for a 5-h postprandial period was obtained from 6-day ambulatory
CGM and used for iBolus calculation in 12 patients with type 1 diabetes. In a double-blind, crossover study each patient
underwent four meal tests with 40 g or 100 g of carbohydrates (CHOs), both on two occasions. For each meal, the iBolus or the
traditional bolus (tBolus) was given before mealtime (t0) in a randomized order. We measured the postprandial glycemic
response as the area under the curve of plasma glucose (AUC-PG0–5h) and variability as the individual coefficient of variation
(CV) of AUC-PG0–5h. The contribution of the insulin-to-CHO ratio, CHO, plasma glucose at t0 (PGt0), and insulin dose to
AUC-PG0–5h and its CV was also investigated.
Results: AUC-PG0–5h was similar with either bolus for 40-g (iBolus vs. tBolus, 585.5– 127.5 vs. 689.2– 180.7mg/dL$h) or 100-g
(752.1 – 237.7 vs. 760.0– 263.2mg/dL$h) CHO meals. A multiple regression analysis revealed a significant model only for the
tBolus, with PGt0 being the best predictor of AUC-PG0–5h explaining approximately 50% of the glycemic response. Observed
variability was greater with the iBolus (CV, 16.7 – 15.3% vs. 10.1 – 12.5%) but independent of the factors studied.
Conclusions: A CGM-based algorithm for calculation of prandial insulin is feasible, although it does not reduce unpre-
dictability of individual glycemic responses. Causes of variability need to be identified and analyzed for further optimization
of postprandial glycemic control.
Introduction
Achieving near-normoglycemia has been establishedas the main objective for most patients with type 1 dia-
betes mellitus (T1DM).1 However, insulin dosing still remains
as an empirical process, and its success is highly dependent on
the patients’ and physicians’ skills, either with multiple daily
injections or with continuous subcutaneous insulin infusion
(CSII), the current gold standard of insulin treatment.
Postprandial glucose control is a challenging issue in
everyday diabetes care. Indeed, postprandial glucose excur-
sions are the major contributors to plasma glucose (PG) var-
iability in subjects with T1DM, and the poor reproducibility of
postprandial glucose response is burdensome for patients and
healthcare professionals.2
During the past 10–15 years, there has been an exponen-
tially increasing use of technology in diabetes care with the
expectation of making life easier for patients with diabetes.
Some tools have been developed to facilitate the prandial
bolus calculation, such as the ‘‘bolus advisors.’’ More recently,
the availability of continuous glucose monitoring (CGM) has
opened new scenarios for implementation of more effective
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strategies of insulin treatment. This may be particularly rele-
vant to CSII-treated patients for whom the information from
the CGM may be used for fine-tuning of the insulin infusion
(‘‘sensor-augmented pump’’). Results from clinical studies of
preliminary models of sensor-augmented pump suggest that
they may be effective in improving metabolic control, espe-
cially when included as part of structured educational pro-
grams aiming at patients’ empowerment.3,4
The algorithms implemented into current bolus advisors
(like the Accurate Insulin Management [AIM] system and its
modifications)5–7 are based on mean populational values es-
timated from nonrandom samples of CSII-treated patients.
Individualization of the algorithms’ parameters is largely
empirical and is made by correcting mean populational val-
ues for weight and mean total daily insulin dose as an esti-
mation of the personal mean insulin sensitivity. This results in
an acceptable estimation of the mean insulin-to-carbohydrate
(I:CHO) ratio (i.e., the prandial insulin need). However, in this
algorithm the intra-individual glycemic variability due to
variations in insulin sensitivity (between-day changes), esti-
mation and/or absorption of carbohydrates (CHOs), and in-
sulin absorption is not taken into account.
Currently, the availability of information from CGM may
be used for characterization of an individualized postprandial
prediction model and also for development of strategies to
deal with the uncertainty of postmeal glycemic response.
Recently, a nonheuristic CGM-based algorithm to deal with
postprandial glycemic control, the iBolus,8 has been tested in
silico with positive results.9 The algorithm is based on interval
techniques (Set Inversion Via Interval Analysis [SIVIA]),10
which allow for explicit consideration of intrapatient vari-
ability as interval quantities in model parameters. Calcula-
tion of a feasible set of insulin dose strategies (bolus plus
increment/reduction of basal rate) to fulfill the given con-
straints on postprandial glycemia is then performed accord-
ing to the patient’s prediction model obtained from CGM.
The present study was planned to validate clinically the
iBolus algorithm for prandial insulin dosing in comparison
with a currently available traditional I:CHO ratio-based
standard bolus (tBolus) in T1DM subjects using CSII.
Subjects and Methods
This was a randomized, prospective, single-center, double-
blinded, two-way crossover study. Twelve subjects with
T1DM under long-term intensive insulin treatment with CSII
(nine women; 41.8 – 7.3 years old; diabetes’ duration,
20.2 – 10.3 years; body mass index, 25.1 – 2.8 kg/m2; glyco-
sylated hemoglobin [A1C], 8.0 – 0.6%; basal insulin dose,
0.8 – 0.3U/h; I:CHO ratio, 1.3 – 0.5U/10 g of CHO [mean–
SD]) were studied in the hospital (inpatient study) following a
period of ambulatory CGM. At the time of the study, all of the
subjects were free at the screening of any significant micro-
angiopathic complication or any signs or symptoms of auto-
nomic neuropathy, as evaluated using a standard battery of
cardiovascular tests.11 The study was carried out according to
the Declaration of Helsinki after written informed consent
was obtained from all subjects and approved by the local
institutional review board.
All volunteers were studied in the hospital on four different
occasions in a random, computer-generated sequence. Each
subject underwent a block of two 40-g CHO and a block of
two 100-g CHO mixed-meal tests, each one at 1–2-week
intervals, thus completing the four experiments in a mean of
6 weeks. The mixed meals had the same relative macronu-
trient composition (50% CHO, 35% fats, and 15% proteins). In
both the 40-g CHO and 100-g CHO experiments, the patients
received in a randomized order a tBolus, based on the indi-
vidual I:CHO ratio (as suggested by the CSII built-in bolus
calculator), or an iBolus, based on CGM and SIVIA. Both the
involved investigators and patients were blinded regarding
the bolus administration procedure during test meals. An
independent unblinded investigator kept the randomization
list and was in charge of administrating the prandial insulin
the day of the in-hospital meal study.
Prior to each block ofmeal tests, subjects underwent at least
two outpatient 6-day periods of CGM monitoring for the
identification (the first 3 days) and validation (the last 3 days)
of an individualized model to be used in the prediction of the
5-h postprandial period (0–5-h PP) (Fig. 1).12 In order to ac-
count for intrapatient variability, a prediction model with
interval parameters9 was calculated from the previous iden-
tifiedmodel considering 20% uncertainty in insulin sensitivity
and 10% in CHO estimation. The interval model was vali-
dated during the last 3 days of CGM,where the patients had a
standardized meal daily (40-g, 60-g, or 100-g CHO content,
the same composition of the inpatient study).12 Finally, con-
straints on PG were posed, and the SIVIA algorithm led to a
three-dimensional set of solutions that contained all the basal-
bolus combinations for maintaining PG between 90 and
180mg/dL for the given meal, according to the prediction
model (Fig. 2).8,9 The solution set may contain profiles either
increasing (dual-wave bolus) or decreasing (temporal basal
decrement bolus or superbolus,9 as suggested by Walsh and
Roberts13) postprandial basal rate as required to fulfill the
constraints for the specific patient (Fig. 2). To test the ro-
bustness of the algorithm, on the days of the inpatient mixed-
meal study, one of the most aggressive solutions of each set
(the one containing the greatest bolus dose) was administered.
However, it is worth noting that the maximum bolus dose
from the set of solutions was independent of the tBolus.
On the days of the mixed-meal study, subjects were ad-
mitted to the Endocrine Clinical Research Center of the Clinic
University Hospital of Valencia, Valencia, Spain, at 09:00 h.
They were put in the sitting position, and two venous lines
were prepared: one for arterialized venous blood sampling14
and the other for insulin or glucose infusion, if required. In-
deed, to ensure comparable metabolic conditions between
studies, where appropriate, subjects received an intravenous
infusion of regular human insulin following a feedback pro-
cedure to maintain PG close to 90mg/dL until the beginning
of the studies at 13:00 h (time 0 [t0] of the study). Then, the test
mixed-meal was consumed in 15–20min. At the same time,
insulin was administered following the randomization
schedule, and PGwasmonitored for 5 h, until the end of study
at 18:00h (time 300min). In order to avoid hypoglycemia
during time 0–300min, a controlled glucose infusion was
started if PG fell below 75mg/dL, and the premeal glycemic
levels were maintained (euglycemic clamp).
The area under the curve (AUC) of PG during the whole
experiment (AUC-PG0–5h) was calculated as a measure of the
overall glucose-lowering efficacy of the mealtime insulin
(iBolus or tBolus, in 40-g and 100-g CHO meals). In addition,
the AUC of the glucose infusion rate (AUC-GIR0–5h)
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represented a measure of the hypoglycemic exposure for
each modality of insulin administration. Consequently, the
lower the AUC-PG0–5h without risks of hypoglycemia, the
greater the effectiveness of the prandial insulin administra-
tion to control the meal-related glucose excursion. The AUC
of PG above the threshold of 140mg/dL (AUC-PG > 140) was
computed as an indicator of meal-induced hyperglycemic
risk.
As a measure of the outpatient glycemic control, the AUC
of the 0–5-h PP was calculated from the CGMdata (interstitial
glucose concentrations, AUC-CGM0–5h) of the two 3-day
validation periods.
Variability of the postprandial glycemic response of both the
outpatient and the inpatient data was calculated as the coeffi-
cient of variation (CV) of the AUC-CGM0–5h and of the AUC-
PG0–5h. Glucose concentrations at t0 (Gt0 and in-hospital PGt0),
the mean prandial insulin dose (Insulin dose0–5h), and their
respective CVs (CV-Gt0, CV-PGt0, and CV-Insulin dose0–5h)
were computed as well, as potentially related to variability of
postprandial glucose.
A multiple linear regression analysis was performed to
assess the parameters that best predicted the glycemic re-
sponse. The model included those parameters usually con-
sidered for the optimization of insulin treatment (the I:CHO
ratio, the amount of CHO, Gt0, or PGt0) and a set of clinical
variables (body mass index, diabetes’ duration, and A1C), as
independent variables. Although the Insulin dose0–5h cannot
be considered independent from the other parameters, it was
included in the model to account for potential nonlinearity of
insulin pharmacodynamics (in relation to insulin dose) and
for the effect of manual bolus administration and/or errors in
the actual dose. In the inpatient study, only one 40-g CHO
meal and one 100-g CHOmeal were available for each type of
treatment, and postprandial variability was determined as the
CV of the 40-g AUC-PG0–5h and the 100-g CHO AUC-PG0–5h
for either the iBolus or the tBolus. For this reason, mean values
FIG. 1. (A) The identification protocol and (B) one of the two 3-day validation periods of Patient 2. (A) First, a mathematical
model of the patient is derived from an ambulatory identification protocol with continuous glucose monitoring. Five-hour
(300-min) lunch postprandial periods from 3 days were considered for identification following the protocol listed. Basically,
identification is achieved through separation of meal from insulin dynamics by administering the bolus either 30min before
or 120min after the meal. For safety reasons, this was done depending on the prevailing glucose concentrations (see Laguna
et al.12). (B) Postprandial continuous glucose monitoring data from 3 additional days were used for model validation, where
intrapatient variability was considered to be caused by day-to-day variations in insulin sensitivity and by the uncertainty in
the estimation/absorption of carbohydrate of the meal. As a result, a model with interval parameters was derived charac-
terizing intra-individual variability. This model predicts a range of postprandial glycemic excursions that the patient may
exhibit (the area between the dashed lines). The fitted line represents the model prediction without considering uncertainty,
whereas the measured line is the actual postprandial glucose profile from the continuous glucose monitoring. Color images
available online at www.liebertonline.com/dia
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were used, and the CHO factor was excluded from the anal-
ysis. The AUC-CGM0–5h, AUC-PG0–5h, and their respective
CVs were the dependent variables.
The 6-day CGM period for model identification and vali-
dation was carried out with the Dexcom! (San Diego, CA)
Seven Plus". During the in-hospital meal tests, PG was
measured by means of a YSI 2300 STAT Plus (YSI Inc. Life
Sciences, Yellow Springs, OH) every 5–15min, depending on
the prevailing blood glucose concentrations.
All data were subjected to repeated-measures analysis of
variance with Huynh–Feldt adjustment for nonsphericity.15
The analysis of variance model included the sequence of
studies as a between-subjects factor, whereas test condition
(iBolus vs. tBolus), CHO content of the meal (40-g and 100-g
CHO conditions), and time (where appropriate) were the
within-subjects factors. Subjects were entered in the model as
random factors nested into the sequence. Post hoc comparisons
with a nominal significance level of 0.05 (Newman–Keuls test)
were carried out to pinpoint specific differences on significant
interaction terms. The coefficient of determination R2 was re-
ported as a measure of the proportion of variability in the
glycemic response that was accounted for by the statistical
model. Data in the text were expressed as mean– SD values,
and those in the figures asmean– SE values. Statistical analysis
was performed using NCSS (Kaysville, UT) software (2007).
Results
The iBolus algorithm resulted in a clinically although not
statistically significant approximately 30% greater mean in-
sulin dose (bolus+ 0–5-h PP basal) compared with the tBolus.
The bolus dose accounted for the whole increment in the 40-g
CHO meals (bolus+ 164%; basal - 6%; median relative basal
modification, - 41%; interquartile range, - 48%, + 43%),
whereas in the 100-g CHO meals both the basal insulin and
the bolus insulin were equally increased (bolus + 129%;
basal + 133%; median relative basal modification, + 37%, in-
terquartile range, - 59%, + 125%) (Table 1).
Despite different insulin doses, the iBolus and the tBolus
resulted in a similar postprandial glycemic control. Indeed,
the overall 0–5-h PP glycemic exposure (AUC-PG0–5h), the
hypoglycemic risk (AUC-GIR0–5h), and the hyperglycemic
FIG. 2. (A) Based on the patient’s interval model, a collection of feasible insulin infusion profiles leading to a good
postprandial control (plasma glucose 90–180mg/dL) was computed using a Set Inversion Via Interval Algorithm (SIVIA).
Insulin infusion profiles were characterized by the amount of bolus, a prandial basal insulin rate, and a time of restoration of
basal rate to its baseline. The feasible set was thus a three-dimensional group of solutions (left panel). Any infusion selected
inside the set (grayscale circles of the set of solutions) will fulfill the imposed constraints (right panel) as shown by grayscale
lines, which represents the predicted glycemic excursions following the selected solutions. (B) A solution with the highest
possible bolus was selected to reach the lower possible postprandial peak. The basal-bolus combination with maximum bolus
was selected from a two-dimensional projection of the feasible set, and then the midpoint of the feasible basal restoration time
interval was selected. In this example, this selection resulted in a superbolus. However, the greatest bolus of the feasible set
may be lower, and the lowest basal rate of the set may be greater than the usual patient’s dose, resulting in solutions different
from the superbolus. Color images available online at www.liebertonline.com/dia
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risk (AUC-PG > 140) were not different with either method of
prandial insulin calculation (Table 1). PG and the GIR time
series showed an apparent trend for better glycemic control
and a slightly greater risk of hypoglycemiawith the iBolus, but
only when the 40-g CHO meal was consumed (Fig. 3).
However, this difference did not reach statistical significance.
Preprandial glucose concentrations were not different be-
tween studies, and CV-PGt0 was small as a result of the insulin
feedback procedure (mean intravenous insulin dose infused
before the bolus administration 0.05– 0.06 and 0.04– 0.04mU/
kg/min for iBolus and tBolus, respectively; P= 0.91). However,
the 0–5-h PP glycemic response varied in a wide range with
both the iBolus (median CV, 14.7%; interquartile range, 4.5–
27.9%) and the tBolus (median CV, 5.4%; interquartile range,
3.3–12.7%) (Table 2). Glucose variability was significantly
greater with the iBolus (Table 2), likely because of the wider
Table 1. Insulin Dose and the Area Under the Curves of Plasma Glucose, Plasma Glucose Above 140 mg/dL,
and Glucose Infusion Rate of the 5-H Postprandial Period for the iBolus and the tBolus
40 g of CHO 100 g of CHO Difference for iBolus – tBolus [CI] for
Parameter iBolus tBolus iBolus tBolus 40 g of CHO 100 g of CHO P valuea
Insulin dose0–5h
b 9.9 – 3.4 7.4 – 2.1 18.0 – 6.7 13.8 – 4.3 2.6 [- 0.7; 5.9] 4.1 [- 0.06; 8.3] 0.32
Bolus dose (7.1 – 2.8) (4.3 – 1.5) (13.9 – 7.1) (10.8 – 3.8)
AUC
PG0–5h 585.5– 127.5 689.2 – 180.7 752.1– 237.7 760.0– 263.2 - 103.6 [- 233.3; 22.0] - 7.9 [- 109.5; 93.7] 0.07
GIR0–5h 150.1– 134.5 54.0 – 87.4 88.9 – 195.5 56.0 – 121.1 96.1 [- 78.5; 270.8] 32.9 [- 141.7; 207.6] 0.45
PG> 140mg/dL 37.2 – 63.5 77.5 – 123.8 141.3– 182.8 144.6– 217.7 38.9 [- 109.3; 31.3] - 2.6 [- 72.9; 67.7] 0.29
Data are given for the 40-g carbohydrate (CHO) and the 100-g CHO meals and expressed as mean – SD values. Difference between
treatments is reported along with its confidence interval (CI).
aP value is from analysis of variance for repeated measures.
bInsulin dose is given in units.
AUC, area under the curve; GIR, glucose infusion rate (in mg/kg); PG, plasma glucose (in mg$h/dL).
FIG. 3. (Top panel) Plasma glucose (in mg/dL) and (bottom panel) exogenous glucose infusion rate (mg/dL/min) for
either the iBolus or the tBolus. For the sake of clarity the 40-g and 100-g carbohydrate (CHO) meals are presented separately.
However, each patient underwent four studies following a two-way crossover design. Data are mean– SE values. The P value
is from analysis of variance for repeated measures.
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range of insulin doses administered (Table 1). In the outpatient
setting, 0–5-h PP intrasubject glucose variability was greater
(median CV, 30.4%; interquartile range, 18.1–37.8%), as ex-
pected, because of less controlled conditions and the use of the
less accurate CGM data instead of capillary glucose as the end
point. It is interesting that glucose variability was associated
with a high inconsistency in Gt0 being independent of the CHO
content of the meal (Table 2).
When the tBoluswas considered, amultiple linear regression
analysis revealed a significantmodel both in the outpatient and
the inpatient setting (adjusted R2= 0.51 and 0.49, respectively).
Preprandial glucose concentration was the variable that best
predicted AUC-CGM0–5h and AUC-PG0–5h, being positively
correlated and explaining about 50% of glycemic response,
whereas insulin dose, I:CHO, and CHO were poor predictors
(Table 3). Diabetes’ duration, A1C, and body mass index did
not correlate to postprandial glycemic response and were re-
moved from the analysis to avoid overfitting (Table 3). It is
interesting that when data from the iBolus were analyzed, no
significant correlation was observed between the considered
independent variables and AUC-PG0–5h.
Finally, variability did not appear to be explained by
the variables considered, either with the tBolus or the iBolus
(Table 3). Unexplained variability accounted for most of the
Table 2. Intrasubject Variability of the Postprandial Glycemic Response Reported as the Intra-Individual
Coefficient of Variation of the 5-H Postprandial Period
CV
Gt0/PGt0 (mg/dL)
a Insulin dose (U) AUC0–5h (mg/dL$h)
b
Outpatient CGM
Overall 32.3 – 8.5% (128.7 – 9.7) 28.7 – 4.3% (10.7 – 3.3) 29.6 – 11.8% (769.5 – 137.3)
40-g CHO 22.1 – 11.8% (129.3 – 33.2) 12.7 – 14.8% (8.4 – 3.2)c 21.0 – 13.6% (754.1 – 216.6)
60-g CHO 27.2 – 9.2% (126.9 – 33.0) 7.3 – 6.3% (10.8 – 2.8)c 22.1 – 15.8% (732.1 – 205.4)
100-g CHO 28.8 – 15.9% (133.4 – 35.9) 4.8 – 4.1% (14.2 – 4.7)c 21.7 – 20.8% (823.2 – 189.8)
P valued 0.45 (0.86) 0.73 (< 0.01) 0.98 (0.76)
Inpatient PG
Overall 6.4 – 2.5% (101.9 – 4.1) 40.1 – 11.6% (12.3 – 3.6) 14.5 – 10.5% (696.7 – 175.3)
iBolus 6.7 – 3.7% (101.2 – 4.4) 39.5 – 24.9% (13.9 – 4.4) 16.7 – 15.3% (668.8 – 162.7)
tBolus 5.6 – 5.0% (102.5 – 5.5) 42.8 – 3.3% (10.6 – 3.2) 10.1 – 12.5% (724.6 – 198.7)
P valued 0.36 (0.43) 0.65 (0.007) 0.04 (0.07)
Data are mean– SD percentage values. The mean– SD absolute values are given in parentheses for glucose at t0 (Gt0 for outpatient and PGt0
for inpatient data), insulin dose, and area under the curve (AUC) of the 5-h postprandial period (0–5 h) for continuous glucose monitoring
(CGM) and plasma glucose (PG) for completeness. For the inpatient study, data are from the 40-g and 100-g carbohydrate (CHO) meals
(iBolus is compared with tBolus regardless of the CHO content of the meal).
aGt0 is interstitial glucose from outpatient CGM, PGt0 plasma glucose from inpatient PG.
bCGM glucose for outpatient CGM, PG for inpatient data.
cP< 0.05 for post hoc comparisons.
dP values are from analysis of variance for repeated measures.
CV, coefficient of variation.
Table 3. Variation in Postprandial Glycemic Responses (and Their Respective Coefficients
of Variation) Analyzed Through Multiple Regressions
Outpatient CGM Inpatient PG
AUC-PG0–5h CV AUC-PG0–5h
AUC-CGM0–5h CV AUC-CGM0–5h iBolus tBolus iBolus tBolus
R2 (R2
adjusted)
P
value
R2 (R2
adjusted)
P
value
R2 (R2
adjusted)
P
value
R2 (R2
adjusted)
P
value
R2 (R2
adjusted)
P
value
R2 (R2
adjusted)
P
value
Full model 0.57 (0.51) < 0.0001 0.04 (0.000) 0.88 0.11 (0.00) 0.81 0.63 (0.49) 0.038 0.14 (0.00) 0.73 0.17 (0.00) 0.66
Gt0 or PGt0 0.50 < 0.0001 0.008 0.63 0.06 0.47 0.55 0.009 0.005 0.83 0.13 0.29
I:CHO ratio 0.03 0.17 0.006 0.68 0.04 0.99 0.09 0.20 0.03 0.60 0.03 0.60
CHO 0.0005 0.85 0.01 0.52 NA NA NA NA
Insulin dose 0.004 0.59 0.02 0.40 0.02 0.69 0.07 0.25 0.006 0.81 0.02 0.65
Models were built considering the insulin-to-carbohydrate (I:CHO) ratio, preprandial glycemia (glucose at t0 [Gt0] in the outpatient
continuous glucose monitoring [CGM] and plasma glucose [PG] at t0 [PGt0] in the inpatient study), prandial insulin dose, and the amount of
carbohydrate (CHO) (the latter was excluded from the analysis of the inpatient data [see text for details]) as independent variables. The
postprandial glycemic responses (area under the curve [AUC] CGM0–5h for the outpatient and PG0–5h for the inpatient study) and their
respective coefficients of variation (CVs) were the dependent variables. The coefficient of determination R2 is reported along with its P value
(by analysis of variance).
NA, not applicable.
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observed variability of the glycemic response. Indeed, a plot of
the D Insulin dose versus the DAUC-PG0–5h (D as iBolusminus
tBolus) revealed a poor correlation with a sometimes unex-
pected direct relationship between the two variables (Fig. 4):
the Pearson correlation coefficient was 0.09 (R2= 0.008,
P= 0.68), and the slope (the estimated change in DAUC-PG0–5h
per unit change in D Insulin dose0–5h) was 3.15 with a 95%
confidence interval that included the 0 value [- 12.6; 18.9].
Discussion
In this proof-of-concept study in CSII-treated patients with
T1DM, a CGM-based strategy for prandial insulin calculation
was tested and compared with the traditional prandial bolus
procedure. Results seem to indicate that (1) CGMmay be used
to obtain an individual model of postprandial glycemic re-
sponse,12 (2) this model can be used for prandial insulin
dosing, and (3) CGM-based insulin delivery results in a
postprandial glycemic control similar to that achieved by
standard bolus calculators. These results are encouraging and
open the way to larger clinical studies aimed at validating less
user-dependent strategies for prandial insulin dosing. How-
ever, several aspects of this study and its limitations deserve
detailed discussion.
First of all, model identification was performed using
models from the literature,16–18 which were obtained through
the analysis of a limited amount of data from small clinical
studies.16,19 In addition, not only the quality of the CHO but
also the proteins and fats content of the meal can significantly
affect glycemic postprandial response.20–22 Consequently,
available models are presumably specific to the meal used in
the experiment and may not apply to meals of different
composition, limiting prediction capabilities of the individual
model derived from CGM. This may explain the differences
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FIG. 4. Intra-individual relative changes in postprandial glucose response to different insulin doses while maintaining the same
meal. Relative change (Delta) in insulin doses for both the 40-g and the 100-g carbohydrate meals ([iBolus – tBolus]/tBolus) are
represented as the xvariable. The relativeDelta area under the curve of plasmaglucose for the 5-h postprandial period (AUC-PG0–5h)
([AUC_iBolus – AUC_tBolus]/AUC_tBolus) is the y variable. The ‘‘feasible’’ quadrants should be the upper left and the lower
right: the lesser the insulin dose administered, the greater the postprandial glucose response; the greater the insulin dose
administered, the lower the glucose response. However, we can see how giving more insulin to the same subject in some cases
resulted in paradoxically higher plasma glucose (Subjects 3, 4, 6, and 10), whereas a lower (Subject 8) or the same (Subjects 5 and
11) insulin dose was associated with lower plasma glucose. This highlights the role of intra-individual glucose variability on
postprandial glucose control in subjects with type 1 diabetes. Color images available online at www.liebertonline.com/dia
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between the in silico9 and the present clinical validation of the
iBolus. Indeed, in the former the iBolus postprandial basal
insulin rate was consistently reduced compared with the
tBolus, to compensate for the greater bolus dose (temporal
basal decrement bolus or superbolus). However, this was
not the case in this study where, because of the heterogeneity
of the real patients, the iBolus resembled either the superbolus
or the dual-wave bolus according to the prediction model for
each patient and meal. Nevertheless, the iBolus algorithm has
at least two advantages: (1) it can consider uncertainty in the
models’ parameters. This means that individual variations in
insulin sensitivity, meal absorption, or errors in the estimation
of the amount of ingested CHO (among other factors) can be
considered (or at least partially compensated) in insulin dos-
ing. (2) It provides not a single but a set of solutions that,
according to the model, are designed to maintain the patient
in a prespecified glycemic range.8,9 These features may be
relevant in clinical practice because, if the individual models
were good, they would allow for a more robust and safer
insulin administration.23
Despite the limitations of the available models used to
calculate the iBolus, the achieved glycemic control was at
least similar to that obtained with the tBolus. Currently, the
traditional bolus calculation is based on a multiple linear
regressionmodel where individual insulin requirements (the
dependent variable) are based on a few parameters as the
I:CHO ratio, the amount of the CHO of the meal, the cor-
rection factor/preprandial glycemia, and, when bolus ad-
visors are used, also the insulin onboard.6,7 Linearity and
reproducibility of the postprandial glycemic response are
assumed in this procedure as the amount of CHO and/or the
preprandial glycemia increase the insulin dose rises linearly,
whereas it is reduced proportionally to the insulin onboard.
If this model were valid, the calculated insulin dose would
result in similar postprandial glycemic response indepen-
dent of the ingested CHO and preprandial glucose. Our re-
sults indicate that the assumption of linearity is only true
regarding the amount of CHO of the meal. In fact, the tBolus
postprandial glycemic control was independent of the CHO
of the meal under both outpatient and inpatient conditions
(Tables 1 and 3).
On the other hand, higher preprandial glucose appeared to
be predictive of higher postprandial glucose, and preprandial
glycemia explained about 50% of the observed variability
(Table 3, outpatient and tBolus inpatient studies). One possible
explanation of our finding could be the nonlinearity of the
correction factor along the whole clinical range of insulin dose
and PG. However, correction insulin dose is usually small and
seldom greater than 10–15% of the total daily dose. Therefore,
nonlinearity of insulin action per se hardly explains the effect
of preprandial glucose. Additionally, this effect persisted also
in the inpatient study despite the fact that very similar pre-
prandial PG concentrations were ensured through insulin
feedback (Table 3, tBolus column). A more suitable explana-
tion is that the different preprandial glucose level is repre-
sentative of different internal states of the patient, likely due to
different degrees of insulinization or insulin sensitivity not
being effectively compensated by the correction factor. In
contrast, when the iBolus was administered the correlation
between preprandial glucose and postprandial glycemia dis-
appeared. This might be due to the greater complexity of the
models used for the individualization of the treatment, with
the iBolus providing better compensation for those variables
represented by preprandial glucose. Nevertheless, neither
glycemic control nor glycemic variability benefited from this
feature of the iBolus, likely because of the poor reproducibility
of postprandial glucose response originated by factors not
represented in the model (nonmodeled dynamics).
The issue of glycemic variability deserves special attention.
Variability is usually attributed to poor reproducibility of
insulin absorption,24 day-to-day variations of insulin sensi-
tivity, inaccurate estimation of the CHO content of the meal,
different meal composition,20–22 and mistakes in insulin ad-
ministration. Our data from outpatient CGM showed that
mean variability of day-to-day intra-individual postprandial
glycemic response was greater than 100% (CV near to 30%)
despite theoretically standardized conditions. Part of the
outpatient glycemic variability may be explained by modest
differences in the glycemic index of the meals consumed at
home (median glycemic index, 48; range, 42–60),21,22 slightly
different preprandial glycemia, and inaccurate glucose esti-
mations from the CGM devices.
However, in the inpatient study all those factors were
controlled before administration of either the iBolus or the
tBolus, and, under these conditions, clinically significant dif-
ferences in the insulin dose using different strategies (30%
greater with the iBolus compared with the tBolus [see Tables 1
and 2]) achieved similar glycemic control (measured as
plasma, not interstitial, postprandial glucose concentrations).
In this regard, a recent study by Pan´kowska et al.25 investi-
gated the effect of considering proteins and fats on post-
prandial glucose. Results demonstrated lower postprandial
glucose with greater insulin dose but with higher variability
(from their data a blood glucose SD of 45–90mg/dL can be
figured out). However, preprandial blood glucosewas greater
in the group receiving less insulin, making it difficult to per-
form a fair comparisonwith our study.Moreover, Pan´kowska
et al.25 adopted a parallel design, preventing calculation of the
intra-individual glucose response variability induced by dif-
ferent insulin doses. In contrast, in the present study the
glycemic response to the same meal was not different despite
the greater iBolus insulin dose. At the individual level, we
observed nonsense responses, with the greater insulin dose
resulting in higher postprandial glucose as well as the lower
insulin dose achieving lower glycemic values. This must be
regarded as "unexplained" variability, which makes it very
difficult to control postprandial glucose response, whatever
the model used for insulin dosing: the classical multiple re-
gression model currently implemented in clinical practice, or
new proposals.
In conclusion, theoretical feasibility of CGM-based insulin
administration has been demonstrated in CSII-treated pa-
tients with T1DM. However, high intrasubject variability ac-
counts for the greatest part of unpredictability of postprandial
glycemic control and remains a barrier for the implementation
of more effective insulin treatments. Differences in glucose
responses to the same meal may be partially explained by
differences in the preprandial metabolic status of the subject,
as represented by premeal glucose concentrations. However,
the major part of variability still remains unexplained, and its
determinants should be investigated and integrated into new
strategies for safer and more efficient insulin administration.
Our method of insulin dosing based on the SIVIA algorithm,
which allows for consideration of uncertainty in the
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postprandial glucose response, is a forward step in prandial
insulin calculation. When determinants of variability are
known, they could be easily incorporated in the algorithm as
interval parameters aiming at more robust insulin dosing
according to the individual patient model. However, obtain-
ing individualizedmodels of postprandial glucose response is
still too complex and must be simplified before CGM-based
bolus advisors are introduced for large-scale validation
studies.
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